GH Research Stock (NASDAQ:GHRS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$6.53

52W Range

$5.05 - $14.99

50D Avg

$9.53

200D Avg

$9.83

Market Cap

$337.66M

Avg Vol (3M)

$40.35K

Beta

0.79

Div Yield

-

GHRS Company Profile


GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

49

IPO Date

Jun 25, 2021

Website

GHRS Performance


GHRS Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-41.22M$-30.55M$-15.10M
Net Income$-35.59M$-7.13M$-9.21M
EBITDA$-41.22M$-37.73M$-15.08M
Basic EPS$-0.68$-0.14$-0.21
Diluted EPS$-0.68$-0.14$-0.21

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
CGEMCullinan Oncology, Inc.
IKNAIkena Oncology, Inc.
RCUSArcus Biosciences, Inc.
MLYSMineralys Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
CSBRChampions Oncology, Inc.
JANXJanux Therapeutics, Inc.
ANNXAnnexon, Inc.
GLUEMonte Rosa Therapeutics, Inc.
MNOVMediciNova, Inc.
DSGNDesign Therapeutics, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
GPCRStructure Therapeutics Inc.
HOWLWerewolf Therapeutics, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.